- Conditions
- Corneal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 110
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Arcadia, California • Poway, California • Sacramento, California + 33 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Drug
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Edema
- Interventions
- dexamethasone Intravitreal Implant, ranibizumab
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Age-related Macular Degeneration
- Interventions
- AGN-150998, ranibizumab, Sham Injection
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Prism Vision Group
- Other
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Edison, New Jersey
- Conditions
- Glaucoma
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Choroidal Melanoma
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
- Conditions
- Fibrovascular Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Interventions
- ranibizumab (Lucentis)
- Drug
- Lead sponsor
- Retina Associates of Cleveland, Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Neovascularization, Choroidal, Macular Degeneration, Age-Related
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Ranibizumab plus Photodynamic therapy
- Drug
- Lead sponsor
- Illinois Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Oak Park, Illinois
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab, bevacizumab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1,208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 59
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Diabetic Retinopathy
- Interventions
- 670nm PBM, intravitreous VEGF-inhibitors
- Device · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
- Drug · Procedure
- Lead sponsor
- Retina Associates of Florida, P.A.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Age-Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
- Conditions
- CYSTOID MACULAR EDEMA
- Interventions
- Ranibizumab,, Triamcinolone acetonide
- Drug
- Lead sponsor
- Soll Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Macular Edema, Uveitis
- Interventions
- triamcinolone, ranibizumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Brandon G. Busbee, MD
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Macular Edema, Diabetic
- Interventions
- Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina